Trials / Unknown
UnknownNCT00532727
Triple Negative Breast Cancer Trial
Triple Negative Trial: A Randomised Phase III Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic or Recurrent Locally Advanced ER-, PR- and HER2- Breast Cancer.
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Institute of Cancer Research, United Kingdom · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether there is greater activity for carboplatin than a taxane standard of care (docetaxel) in women with ER-, PR- and HER2- breast cancer. The trial aims to recruit between 370 and 450 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carboplatin | AUC 6 every 3 weeks for six cycles (18 weeks) |
| DRUG | Docetaxel | 100mg/m2 every 3 weeks for six cycles (18 weeks) |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2016-03-01
- Completion
- 2020-03-01
- First posted
- 2007-09-20
- Last updated
- 2019-02-20
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00532727. Inclusion in this directory is not an endorsement.